XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s Ojemdatm (Tovorafenib) for Relapsed or Refractory Braf-Altered Pediatric Low-Grade Glioma (Plgg)
隨着美國食品藥品管理局加快批准Day One's Ojemdatm(Tovorafenib)治療復發或難治性Braf改性小兒低度神經膠質瘤(Plgg),XOMA實現了900萬美元的里程碑